155 related articles for article (PubMed ID: 24357745)
21. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
Baselga J; Arteaga CL
J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
[TBL] [Abstract][Full Text] [Related]
22. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer.
Khalil MY; Grandis JR; Shin DM
Expert Rev Anticancer Ther; 2003 Jun; 3(3):367-80. PubMed ID: 12820779
[TBL] [Abstract][Full Text] [Related]
23. Review of epidermal growth factor receptor biology.
Herbst RS
Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):21-6. PubMed ID: 15142631
[TBL] [Abstract][Full Text] [Related]
24. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy.
Morgillo F; Bareschino MA; Bianco R; Tortora G; Ciardiello F
Differentiation; 2007 Nov; 75(9):788-99. PubMed ID: 17608727
[TBL] [Abstract][Full Text] [Related]
25. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors.
Marshall J
Cancer; 2006 Sep; 107(6):1207-18. PubMed ID: 16909423
[TBL] [Abstract][Full Text] [Related]
26. Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab.
Moon C; Chae YK; Lee J
Exp Biol Med (Maywood); 2010 Aug; 235(8):907-20. PubMed ID: 20562132
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors.
Krozely P
Clin J Oncol Nurs; 2004 Apr; 8(2):163-8. PubMed ID: 15108418
[TBL] [Abstract][Full Text] [Related]
28. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
Lenz HJ
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):5-13. PubMed ID: 16736978
[TBL] [Abstract][Full Text] [Related]
29. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy.
Okamoto I
FEBS J; 2010 Jan; 277(2):309-15. PubMed ID: 19922468
[TBL] [Abstract][Full Text] [Related]
31. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
32. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents.
Noonberg SB; Benz CC
Drugs; 2000 Apr; 59(4):753-67. PubMed ID: 10804033
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor as a therapeutic target in colorectal cancer.
Cohen RB
Clin Colorectal Cancer; 2003 Feb; 2(4):246-51. PubMed ID: 12620146
[TBL] [Abstract][Full Text] [Related]
34. The epidermal growth factor receptor pathway and its inhibition as anticancer therapy.
Janmaat ML; Giaccone G
Drugs Today (Barc); 2003; 39 Suppl C():61-80. PubMed ID: 14988746
[TBL] [Abstract][Full Text] [Related]
35. Emerging combination therapies to overcome resistance in EGFR-driven tumors.
Ratti M; Tomasello G
Anticancer Drugs; 2014 Feb; 25(2):127-39. PubMed ID: 24113593
[TBL] [Abstract][Full Text] [Related]
36. Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.
Park AK; Francis JM; Park WY; Park JO; Cho J
Oncotarget; 2015 Apr; 6(11):8839-50. PubMed ID: 25826094
[TBL] [Abstract][Full Text] [Related]
37. Targeting Epidermal Growth Factor Receptor-Related Signaling Pathways in Pancreatic Cancer.
Philip PA; Lutz MP
Pancreas; 2015 Oct; 44(7):1046-52. PubMed ID: 26355547
[TBL] [Abstract][Full Text] [Related]
38. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.
Bianco R; Troiani T; Tortora G; Ciardiello F
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S159-71. PubMed ID: 16113092
[TBL] [Abstract][Full Text] [Related]
39. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
[TBL] [Abstract][Full Text] [Related]
40. The epidermal growth factor receptor as a target for colorectal cancer therapy.
Lockhart AC; Berlin JD
Semin Oncol; 2005 Feb; 32(1):52-60. PubMed ID: 15726506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]